Ovarian clear cell carcinoma (OCCC) is a type of epithelial ovarian cancer that is strongly associated with endometriosis, resistance against conventional chemotherapy and thus poorer prognosis. The expression of inhibitory member of the ASPP family proteins (iASPP) and Polo-like kinase (PLK)1 were significantly higher in OCCC compared to benign cystadenomas and endometriosis. Both protein expressions were found to correlate with chemoresistance in patients with OCCC while high iASPP expression alone was significantly associated with a poor patient survival. The growth of OCCC cell lines, OVTOKO and KK, were inhibited after iASPP silencing. Such effect was related to senescence triggering as evidenced by increased SA-b-Gal staining and p21 WAF1/Cip1 expression. Moreover, knockdown of iASPP induced PLK1 downregulation, whereas either genes' silencing sensitized the cells in response to cisplatin treatment. More prominent apoptosis was induced by cisplatin in OCCC cells after the knockdown of either iASPP or PLK1 as evidenced by the formation of more cleaved caspase 3. Heightened chemosensitivity to cisplatin after iASPP knockdown was further demonstrated in in vivo xenograft model. Additionally, both iASPP and PLK1 were shown to regulate autophagic flux as the induction of LC3B-II and LC3 puncta were much less in OCCC cells with either knockdown. Importantly, inhibition of autophagy also enhanced chemosensitivity to cisplatin in OCCC cells. These findings strongly imply that iASPP and PLK1 affect the chemoresistance of OCCC via the regulation of autophagy and apoptosis. Both iASPP and PLK1 can be potential therapeutic targets for treating OCCC in combination with conventional chemotherapy.
Ovarian cancer is a heterogeneous disease, which comprises different histotypes. One of which is ovarian clear cell carcinoma (OCCC). It is associated with endometriosis and is more likely to develop resistance to conventional chemotherapy such as cisplatin. 1, 2 OCCC is more prevalent in Asia than western countries, accounting for 15-25% of epithelial ovarian cancers. 3 ASPP (the ankyrin repeat, SH3 domain and proline-rich region containing protein) encompasses a family of proteins that is able to modulate p53-mediated transcriptional activity and apoptosis. 4, 5 The inhibitory member of the ASPP family, iASPP, is encoded by PPP1R13L. It is an evolutionarily conserved protein and negatively regulates p53 and p63. 5 The oncogenic role of iASPP has been shown in many cancers. 6, 7 Our previous study has also shown that iASPP was highly expressed in ovarian cancers in comparison to benign and borderline ovarian tumors, and was positively correlated with chemoresistance and poor overall and disease-free survival in ovarian cancer patients. 8 Nevertheless, the underlying mechanisms of iASPP conferring chemoresistance and its specificity in OCCC have yet to be well characterized. Polo-like kinase (PLK) is a family of serine-threonine kinases which regulate mitosis, cytokinesis and cellular responses to DNA damage. 9 Overexpression of PLK1, a predominant form, was found in ovarian cancer and associated with poor prognosis. 10 Systematic searches of electronic databases also revealed high PLK expression in OCCC but details on its functional importance in OCCC were still missing. 11 Interestingly, our in silico analysis using NetPhos has suggested that iASPP may harbor a putative phosphorylation site for the kinase activity of PLK1. This has prompted our own investigation into the functional association between iASPP and PLK1 in OCCC. However, no binding between iASPP and PLK1 could be demonstrated in OCCC (data not shown).
Instead, we are showing how iASPP is affecting the expression of PLK1 in OCCC cells. Autophagy is a lysosomal degradation process responsible for the recycling of nutrients from long-lived proteins and organelles. 12 This process is important for the cellular homeostasis as well as an alternative way of cell death.
Although it is contextual, autophagy is generally believed to be protective of tumor cells against chemotherapy. 13 Autophagy inhibition has been explored as a potential therapeutic approach for cancer therapy in recent decades. 14 Notably, autophagy protein LC3A has been found to correlate with the survival of OCCC patients. 15 This association between higher autophagy induction and poor prognosis implies that interference in autophagy may also be a good therapeutic option for OCCC. In this study, the functional roles of iASPP and PLK1 in OCCC, particularly its effect on cisplatin chemosensitivity, was characterized. In particular, the impact of autophagy in such context was also evaluated. Our findings indicate that iASPP is involved in multiple cellular processes and may act as a therapeutic target to improve the efficacy of cisplatin in OCCC.
Materials and Methods

Cell lines and reagents
Human ovarian clear cell carcinoma cell lines OVTOKO, KK, OVISE, OVMANA and KOC7C were gifts from Dr Hirochi Itamochi (Tottori University, Japan). 2 3), they were purchased from IDT (Coralville, IA), whereas si-iaspp#1, si-iaspp#2 and negative control siRNA (clone ID s21296, s195072 and 4390846) were from Thermo Fisher Scientific.
Transfection and viral infection
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) was used for transfection of expression plasmids or shRNA, whereas siLentFect Lipid Reagent (Bio-Rad) was used for transfection of siRNA. HEK293T cells were transfected with 1 lg shRNA plasmid and auxiliary plasmids, VSVG (Addgene #8454) and dvpr (Addgene #8455), for viral packaging and replaced with fresh medium after 4 hr. The viral particle-containing medium was harvested after an additional 48 and 72 hr incubation period and used to transduce OCCC cells supplemented with 6 mg/ml polybrene (Sigma-Aldrich) for 4 hr each. The knockdown was verified at least 48 hr after the infection. For siRNA transfection, 20 nM siRNA was used to transfect cells for 24 hr and the cells were harvested 48 hr later.
MTT, BrdU incorporation and clonogenic assays
Four thousand cells per well were seeded in a 96-well plate before treatment as indicated. During detection, each well was replaced with 100 mL fresh medium containing 10 mL of 5 mg/mL MTT (Sigma-Aldrich) and incubated 2 hr. The MTT crystals were dissolved in DMSO and the absorbance was measured at 570 nm by using microplate reader (Infinite200, Tecan, Switzerland). BrdU incorporation assay was performed through BrdU Cell Proliferation Assay Kit (Cell Signaling Technology) according to manual instruction. For clonogenic assay, 6000 cells were seeded per well in 6-well plate and allowed to grow for 14 days. Cells were then fixed and stained in Giemsa solution (Merck, Darmstadt, Germany) containing 50% methanol for 30 min prior to counting colonies consisting of at least 50 cells. 17 
Senescence assay
After OCCC cells were infected with viral-base shRNA for 72 hr, senescence was illustrated by the presence of bgalactosidase by using Senescence b-Galactosidase staining kit (Cell Signaling Technology) as per manual instructions. The cell images were captured by Inverted Microscope (Nikon Eclipse TS100).
Sphere forming culture
Cells were trypsinized, centrifuged and suspended with serum-free DMEM/F12 medium supplemented with 5 lg/ml insulin, 10 ng/ml basic fibroblast growth factor (bFGF, Invitrogen) and 20 ng/ml human recombinant epidermal growth factor (EGF, Invitrogen) and 0.4% BSA (Sigma-Aldrich) as previously described. 18 They were grown in ultralow attachment plates (Corning, Corning, NY) for 2 weeks. Passage of viable spheroids were achieved by low-speed centrifugation to separate from dead or single cells. After the treatment as indicated, the viable cells were counted by trypan blue assay.
Xenograft model
Pools of OVTOKO cells with or without stable iASPP downregulation were selected by the addition of 2 lg/ml puromycin (Thermo Fisher Scientific). 
Statistical analysis
Three independent experiments were done for each assay unless indicated. Unpaired Student's t test was performed. All data are expressed as mean 6 standard error of mean (SEM). Statistical analyses on clinical samples were performed on SPSS version 24.0 (SPSS Inc., Chicago, IL). The difference and correlation between different groups or variables were measured through Mann-Whitney and Spearman's test, respectively. Kaplan-Meier method was used to evaluate the survival analysis. A p value of <0.05 was considered statistically significant.
Results
Expression profile of iASPP in OCCC clinical samples and cell lines
A cohort of 50 OCCC, 20 endometriosis and 19 benign mucinous and serous cystadenomas cases, was studied by immunohistochemistry. iASPP expression in OCCC patients was significantly higher than in patients with endometriosis or cystadenomas (p < 0.001, Fig. 1a ), whereas the difference between endometriosis and benign cases was insignificant (p 5 0.384), although the average score in endometriosis was higher. Consistently, most of the OCCC cell lines (4 out of 5) also expressed a higher level of iASPP when compared to normal ovarian epithelial cell lines HOSE 6-3 and HOSE 11-12 (data not shown). The results strongly suggest that iASPP is overexpressed in OCCC, while our cohort also indicates that high iASPP expression was associated with a poor disease-free (p 5 0.003) and overall survival (p 5 0.002) in OCCC (Fig. 1b) . Moreover, significantly higher iASPP level was found in chemoresistant OCCC (p 5 0.041) (Fig. 1b) .
Effect of iASPP on the growth of OCCC cell lines
Two OCCC cell lines, OVTOKO and KK, with high iASPP expression and harboring wildtype TP53 were used to demonstrate the molecular functions of iASPP. 20, 21 Two lentivirus-based shRNAs were used to knock down iASPP in these cell lines (Fig. 2a) . Upon iASPP silencing, progressively less viable cells were observed than the scramble control over a three day incubation period was observed in both OCCC cells (Fig. 2b) . The observed difference in viability stemmed mainly from growth inhibition of the iASPP knockdown cells that had less BrdU incorporated in their DNA, indicating that iASPP downregulation induced less DNA synthesis and thus cell proliferation (Fig. 2c) . Clonogenic assay also demonstrated growth retardation in iASPP silenced OCCC cells since the number of colonies formed in KK cells with iASPP downregulated was significantly less than that of the scrambled control (Fig. 2d) .
While OVTOKO's growth characteristic prevents them from forming discrete and countable colonies, its cell density was reduced after iASPP knocked down when compared with the scrambled control, corroborating the presence of growth inhibition (Fig. 2d) . The effect of iASPP silencing on apoptosis is not prominent in OCCC. There was only a slight increase in cleaved PARP after 48 hr of iASPP knockdown alone, while cleaved caspase 3 was still absent (data not shown). With using PI and Annexin V staining, we showed that neither DNA fragmentation nor apoptosis ( Supporting Information, Fig. 1a ) respectively, increased significantly in iASPP silenced OCCC cells. 
Knockdown of iASPP induced senescence in OCCC cells
Cellular senescence is a phenomenon describing growth arrest that blocks tumor progression. To investigate if iASPP regulates growth arrest through senescence in OCCC, we measured the presence of SA-b-Gal, a marker of senescence, post iASPP silencing. After 72 hr of lentivirus infection, both OVTOKO and KK cells showed more SA-b-Gal staining in iASPP knockdown cells than the scramble control (Fig. 2e) . The expression of p21 WAF1/Cip1 , an inducer for senescence, also increased in OCCC cells with iASPP silencing (Fig. 2f) . Thus, iASPP downregulation inhibits cell growth through enhancing senescence rather than inducing cell death through apoptosis.
Highly expressed PLK1 in OCCC and its effect on cell proliferation Similar to iASPP, OCCC patients expressed a higher PLK1 level than in patients with endometriosis or benign cystadenomas (Fig. 1a) . Additionally, high PLK1 expression in OCCC also correlates with chemoresistance (p 5 0.035, Fig.  3a) . In contrast, PLK1 expression alone showed no association with patient survival but combining both high PLK1 and iASPP expression was linked to poor disease-free (p 5 0.032) and overall (p 5 0.026) patient survival when compared to those with low expression of PLK1 and iASPP (Fig. 3a) . Moreover, high iASPP expression was significantly correlated with high PLK1 level in OCCC (Pearson correlation 5 0.316, p 5 0.003). Knockdown of iASPP was also accompanied by a decrease in PLK1 expression, suggesting a close relationship between iASPP and PLK1 (Fig. 3b) . Furthermore, iASPP affected the expression of cell cycle mediator. Knockdown of iASPP decreased cyclin B1 expression (Fig. 3b) , whereas the level of expression for other mediators, such as cyclin D1 and separase, was similar between the scramble control and iASPP knockdown ( Supporting  Information, Fig. 1b) . Two siPLK1 sequences were used to knock down PLK1 in both OCCC cell lines. The number of viable cells and colonies formed were less as indicated in MTT and clonogenic assays respectively, when compared to cells transfected with the scramble control (Fig. 3cd , and Supporting Information, Fig. 2a) . BrdU incorporation assay also implied that siPLK1 transfection slowed down the DNA synthesis and therefore proliferation in OCCC cells (Fig. 3d) . Similar to iASPP knockdown, PLK1 silencing in OVTOKO and KK cells also led to a decrease in cyclin B1 and Atg5 (Fig. 3e) , strongly implying the existence of crosstalk between PLK1 and iASPP.
Crosstalk between iASPP, PLK1 and autophagy in OCCC As both iASPP or PLK1 knockdown resulted in decreased Atg5, an upstream mediator essential for the elongation of preautophagosomal membrane (Fig. 3be) , 22 it is likely that these two genes may have a role in the regulation of autophagy. Screening through a panel of OCCC cell lines, we noticed that they generally have higher expression level of LC3B-II, an autophagosome membrane protein, than the HOSE cell lines (data not shown). In clinical samples, we have also observed that LC3B and its upstream mediator, Vps34, were present in considerably higher levels in OCCC than benign cystadenoma and endometriosis (p < 0.001, Fig. 4a ). Our results are consistent with findings from Spowart et al. who found that OCCC cells exhibited greater autophagy induction. 15 Similar upregulation on LC3B -II was also observed in our ovarian For cell line models, the autophagy inhibitor-bafilomycin A1 or chloroquine-was used to block the autophagic flux and exaggerate the LC3B-II accumulation. PLK1 silencing generally resulted in less LC3B-II induction with the presence of trace amount of LC3B-I when compared to the scramble controls in both OCCC cells under the influence of autophagy inhibitors, suggesting the autophagy was hindered in OCCC cells after knockdown (Fig. 4b) . Less GFP-LC3 bound puncta were also formed in cells with iASPP or PLK1 downregulation, again indicating that these two proteins affect autophagic activity in OCCC cells (Fig. 4c) . To validate that iASPP and PLK1 affect autophagy through Atg5 interference, shRNAs were used to knock down Atg5 in OVTOKO and KK cells. As expected, the accumulation of LC3B-II was less in OCCC cells with Atg5 silencing in the presence of bafilomycin A1 (Fig. 4d) , supporting that iASPP and PLK1 may mediate autophagy through Atg5.
Autophagy inhibition sensitized OCCC cells toward cisplatin
Autophagy induction affects the chemoresistance in many cancers. 23, 24 Inhibition of autophagy in OCCC cells may therefore improve the chemosensitivity. Spheroid cultures of OVTOKO and KK were used to mimic the 3 D environment to assess their cisplatin sensitivity. Another autophagy upstream mediator, Beclin 1, was also tested to show the effect of autophagy on chemoresistance. Similar to Atg5, Beclin1 silencing resulted in less LC3B-II accumulation in the presence of bafilomycin A1, again indicating that autophagy is being inhibited by its knockdown (Supporting Information, Fig. 2b ). The knockdown of either Atg5 or Beclin1 conferred greater susceptibility to cisplatin on OCCC cells than the scramble controls (Fig. 4e) . Consistently, chemical inhibition of autophagy with bafilomycin A1 enhanced the cytotoxicity of cisplatin on OCCC cells when they were added in combination (Fig. 4f) . Overall, our evidence suggests that autophagy inhibition enhances the sensitivity of OCCC cells to cisplatin treatment.
Downregulation of iASPP and PLK1 enhanced apoptosis inducing effect of cisplatin
We have shown that OCCC patients with poor response to chemotherapy expressed higher levels of iASPP and PLK1 (Figs. 1b and 3a) . OCCC cells with iASPP silencing were more sensitive than the scramble control towards cisplatin at the same concentration under 3 D culturing condition (Fig.  5a ). In the clonogenic assay, the impact of a one-shot, lowdose cisplatin (20 lM) treatment for 24 hr over a 10-14 days incubation period was also more effective in suppressing growth of OCCC cells with iASPP downregulation as the colonies formed in KK cells with iASPP knockdown were significantly less than the scramble control (Fig. 5b) . Similar enhancement in cisplatin cytotoxicity with iASPP knockdown was also achieved in normal 2 D culture and measured by MTT assay ( Supporting Information, Fig. 3a) . The decrease in cell viability was attributed to a stronger apoptotic effect in cells with iASPP downregulation. The concomitant DNA fragmentation and proportion of apoptotic fraction as illustrated by PI and Annexin V staining analyses were more pronounced in iASPP-deficient cells after cisplatin treatment ( Fig. 5c and Supporting Information, Fig. 3b ). At the molecular level, cisplatin treatment of iASPP silenced OCCC cells triggered the formation of more cleaved PARP and Caspase 3 than in those scramble controls, again supporting an increase in apoptotic activities (Fig. 5d) . The increased level of apoptosis could be related to a decrease in Mcl1 expression in OCCC cells with iASPP knockdown (Fig. 5d) . With regard to PLK1, its silencing also potentiated the cisplatin-induced DNA fragmentation in both OVTOKO and KK cells when compared to scramble control (Fig. 6a ). An increase in apoptotic cells with PLK1 knockdown was also demonstrated through Annexin V staining (Supporting Information, Fig. 3b ), whereas molecular changes such as upregulation of cleaved Caspase 3 but decrease in Mcl1 were observed (Fig. 6b) . All evidence indicates that iASPP and PLK1 silencing enhances the apoptotic effects induced by cisplatin. The similar molecular changes observed also support the presence of interaction between iASPP and PLK1. Overexpression of PLK1 partially restored chemoresistance in iASPP-deficient OCCC cells
To illustrate the role of PLK1 in iASPP mediated chemoresistance, a Flag-tagged PLK1 expression plasmid was transfected into OCCC cells along with siRNAs against iASPP. With iASPP silencing and cisplatin treatment, cell viability increased in OVTOKO cells with additional exogenous PLK1 expression when compared to control transfected with empty vector without PLK1 (Fig. 6c) . Consistently, the overexpression of PLK1 in iASPP silenced OVOTOKO cells resulted in less cleaved Caspase 3 forming even after cisplatin treatment (Fig. 6d) . Notably, the level of LC3B-II has also increased slightly with PLK1 upregulation (Fig. 6d) . The data strongly supports that PLK1 can restore, at least partially, the chemoresistance which is hampered by iASPP downregulation in OCCC cells.
Knockdown of iASPP retarded the growth of OCCC xenografts and enhanced cisplatin treatment
The effects of iASPP on tumor growth and chemoresistance were also demonstrated through mice model. Xenografts were derived from OVTOKO cells with or without stably iASPP knockdown after subcutaneously inoculated into nude mice. The average xenograft volume of the iASPP silencing group was significantly smaller than the scramble control group (Fig. 6e) . Treating the mice with cisplatin (4 mg/kg) weekly retarded the growth of xenografts when compared to their corresponding groups with no cisplatin injection (Fig.  6e) . Cisplatin inhibition on xenograft growth was most effective on xenografts with iASPP downregulation, resulting in the smallest tumor size recorded. These results corroborated the in vitro experiments that knockdown of iASPP inhibited the growth of OCCC and improved the efficacy of cisplatin treatment. The weight of mice of different groups was comparable throughout the treatment period (Supporting Information, Fig. 4 ).
Discussion
Although TP53 mutation is common in ovarian cancer especially in the high-grade serous subtype, OCCC belongs to the type I ovarian cancers which harbor wildtype TP53. 25, 26 Therefore, knowledge of negative modulators of wildtype p53 is important for understanding the pathogenesis of this aggressive cancer. We have previously shown that ovarian cancer overexpressed iASPP, whereas downregulation of iASPP in serous ovarian cancer cells led to p53-dependent and p53-independent deleterious effects. 8 In this study, we specifically pinpointed the functional roles of iASPP in OCCC cell growth and chemoresistance. Unlike triggering apoptosis in serous carcinoma cells, iASPP silencing suppressed cell proliferation and induced senescence in OCCC cells. The p53 dependent p21
and cyclin B1 were modulated, respectively, 27 strongly implying that p53 activity was activated once iASPP effect was blocked. In fact, cellular senescence has been reported to be induced by p53 to prevent malignant transformation 28 and iASPP was found to inhibit senescence 29, 30 and is required for epithelial stratification. The effect of iASPP on senescence in OCCC, however, has not been reported.
Interestingly, our results showed that iASPP, PLK1 and autophagy are intertwined under certain circumstances. The expression of iASPP, PLK1 and autophagy proteins Vps34 and LC3B was higher in OCCC than endometriosis and benign cystadenomas as a group. Moreover, both iASPP and PLK1 expression showed correlation with chemoresistant phenotype. Cisplatin is one of the platinum-based agents in conventional chemotherapy but the clinical response of OCCC patients is usually poorer than that of serous adenocarcinoma patients. 31 Our findings suggest that this resistance may be attributed to highly expressed iASPP and PLK1, as the silencing of either gene confers higher sensitivity to cisplatin. PLK1 is important for cell mitosis and is shown to be crucial for tumor growth in different types of cancers. 32 In consistent with our findings, a recent study has demonstrated that PLK1 inhibition caused mitotic slippage in which cyclin B1 was downregulated. 33 Besides, a few studies have reported the roles of PLK1 in cancer chemoresistance. 34, 35 Several PLK1 inhibitors have been developed and evaluated in phase I/II clinical trials, [36] [37] [38] but none has been assessed in OCCC. Additionally, the effectiveness of PLK1 inhibitors were shown to be p53 dependent. 39 The beneficial effects of PLK inhibition were more effective on tumor cells with functional p53 than those with nonfunctional p53 mutations.
Our findings also suggest the existence of crosstalk between PLK1 and iASPP as they share similar molecular changes and affect chemosensitivity. Nevertheless, PLK1 silencing alone showed no induction of senescence in OCCC cells as no change in p21 WAF1/Cip1 was found (data not shown), suggesting that there is discrepancy over other cellular functions. PLK1 was more likely to overlap with iASPPmediated cell survival as overexpression of PLK1 partially rescued the OCCC cells with iASPP knockdown during cisplatin treatment.
ASPP family members have been shown to regulate autophagy in different contexts. ASPP2, a positive modulator on p53, inhibited autophagy to mediate RAS-induced senescence through direct binding of Atg5, 40 whereas iASPP inhibited autophagy in keratinocytes to prevent them from differentiation. 41 In contrast our evidence suggests that iASPP is important for maintaining active autophagy which is favorable in OCCC. Here, we showed that high iASPP expression in OCCC correlates to a more active status of autophagy as illustrated by high Vps34 and LC3B expression. The main reason behind the divergence between the keratinocyte study and our study may be due to the contextual differences among the types of cell lines used. We observed that autophagy is highly active in native OCCC cells with predominant expression of LC3-II, whereas keratinocytes expressed mainly LC3-I. Our iASPP knockdown system resulted in decreased Atg5, which was not seen in the iASPP silenced keratinocyte.
Even though our results suggest that OCCC cells need iASPP to regulate autophagy through Atg5, our co-immunoprecipitation data (not shown) does not support the direct binding of iASPP and Atg5.
Increasing evidence has suggested that autophagy interference provides a novel therapeutic approach in cancer. 42 A study has indicated that ERK activated autophagy conferred cisplatin resistance in serous ovarian cancer cell lines. 43 Chemical blockade of autophagy through inhibitors or Atg5 knockdown showed enhancement of cytotoxicity of cisplatin in OCCC cells in our study. This again raises the potential of including autophagy inhibitors in the chemotherapy of OCCC treatment. Clinically applicable autophagy inhibitors such as chloroquine are available, and they have been tested in combination with other therapeutic agents 14 although information on OCCC cases was not available (ClinicalTrial.-gov). This study provides data supporting exploration of applying autophagy inhibitors in OCCC to improve the efficacy of current chemotherapy. In summary, iASPP is important for the pathogenesis of OCCC and its role in regulating the chemoresistance will also provide insights in the development of novel therapy options.
